-+ 0.00%
-+ 0.00%
-+ 0.00%

Aptahem announces availability of October 2026 shareholder letter

PUBT·10/02/2026 06:53:51
Aptahem announces availability of October 2026 shareholder letter
  • Aptahem announced the release of an October 2026 shareholder letter outlining next steps for drug candidate Apta-1.
  • Letter cited completed Phase 1 showing a favorable safety and tolerability profile, with preclinical anti-inflammatory, antithrombotic, immunomodulatory signals.
  • Planning work started with Prof. Folke Sjöberg on a potential patient study in severe burns; start date not set, financing not secured.
  • Manufacturing update: Hongene produced a test batch using a new conjugation method, targeting ~99% purity, improved yield, lower scale-up costs.
  • Patent Family 2 granted across key markets including the U.S., Japan, China, Europe, with stated term running to 2038; letter also detailed an ongoing rights issue.
  • https://mb.cision.com/Main/12121/4403832/4299287.pdf


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptahem AB published the original content used to generate this news brief via Cision (Ref. ID: 202610020250BITN____UKPR__SV_20261002-BIT-8332-0) on October 02, 2026, and is solely responsible for the information contained therein.